Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity
Activating mutations of FMS-like Tyrosine Kinase 3 (FLT3) occur in a subset of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Gilteritinib, an oral FLT3 inhibitor approved for the treatment of relapsed or refractory AML, has been shown to improve survival and remission rates...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/cric/1976122 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324230325305344 |
|---|---|
| author | Kristi Dutta Ethan D. Kotloff Manu M. Mysore |
| author_facet | Kristi Dutta Ethan D. Kotloff Manu M. Mysore |
| author_sort | Kristi Dutta |
| collection | DOAJ |
| description | Activating mutations of FMS-like Tyrosine Kinase 3 (FLT3) occur in a subset of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Gilteritinib, an oral FLT3 inhibitor approved for the treatment of relapsed or refractory AML, has been shown to improve survival and remission rates compared with salvage chemotherapy. This case report presents two patients initiated on gilteritinib for relapsed AML who developed new onset left ventricular systolic dysfunction. After ruling out other common etiologies, gilteritinib was discontinued due to concern for cancer therapy–related cardiac dysfunction with subsequent improvement in ejection fraction. These cases demonstrate a rare but serious adverse effect of gilteritinib, cardiotoxicity manifested as left ventricular systolic dysfunction, for which more studies are needed to elucidate the underlying pathophysiology. |
| format | Article |
| id | doaj-art-bc76dc53190e4a9c8947cba4eb0f0a0a |
| institution | Kabale University |
| issn | 2090-6412 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-bc76dc53190e4a9c8947cba4eb0f0a0a2025-08-20T03:48:46ZengWileyCase Reports in Cardiology2090-64122025-01-01202510.1155/cric/1976122Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset CardiotoxicityKristi Dutta0Ethan D. Kotloff1Manu M. Mysore2Department of MedicineDepartment of MedicineDivision of Cardiovascular MedicineActivating mutations of FMS-like Tyrosine Kinase 3 (FLT3) occur in a subset of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Gilteritinib, an oral FLT3 inhibitor approved for the treatment of relapsed or refractory AML, has been shown to improve survival and remission rates compared with salvage chemotherapy. This case report presents two patients initiated on gilteritinib for relapsed AML who developed new onset left ventricular systolic dysfunction. After ruling out other common etiologies, gilteritinib was discontinued due to concern for cancer therapy–related cardiac dysfunction with subsequent improvement in ejection fraction. These cases demonstrate a rare but serious adverse effect of gilteritinib, cardiotoxicity manifested as left ventricular systolic dysfunction, for which more studies are needed to elucidate the underlying pathophysiology.http://dx.doi.org/10.1155/cric/1976122 |
| spellingShingle | Kristi Dutta Ethan D. Kotloff Manu M. Mysore Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity Case Reports in Cardiology |
| title | Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity |
| title_full | Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity |
| title_fullStr | Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity |
| title_full_unstemmed | Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity |
| title_short | Heartbreak From Gilteritinib: Two Case Reports of Delayed Onset Cardiotoxicity |
| title_sort | heartbreak from gilteritinib two case reports of delayed onset cardiotoxicity |
| url | http://dx.doi.org/10.1155/cric/1976122 |
| work_keys_str_mv | AT kristidutta heartbreakfromgilteritinibtwocasereportsofdelayedonsetcardiotoxicity AT ethandkotloff heartbreakfromgilteritinibtwocasereportsofdelayedonsetcardiotoxicity AT manummysore heartbreakfromgilteritinibtwocasereportsofdelayedonsetcardiotoxicity |